Equity Sector Funds Very High Risk
The investment objective of the scheme is to seek to generate long term capital appreciation throughinvesting in equity and equity related securities of companies engaged in Pharma and Healthcare.However, there can be no assurance or guarantee that the investment objective of the Scheme would be achieved.
Expert-managed portfolios tailored to your financial goals.
Estimation is based on the past performance
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | 8.1% | 8.47% | -2.98% | -5.82% | 0.32% | 8.11% | 19.48% | 13.8% | 0% | 0% | 10.95% |
| Category returns | 6.83% | 7.45% | 0.03% | -2.3% | 6.38% | 11.92% | 22.96% | 16.06% | 13.74% | 12.95% | N/A |
| Absolute returns | 7.92% | 9.26% | 3.42% | 2.24% | 4.64% | 23.22% | 79.9% | 86.65% | 0% | 0% | 67.3% |
| Rank within category | 5 | 6 | 15 | 16 | 16 | 13 | 10 | 9 | 10 | 5 | N/A |
| Total Schemes in Category | 18 | 18 | 17 | 17 | 16 | 14 | 10 | 10 | 9 | 4 | N/A |
| Sector Funds | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Yearly returns | N/A | -8.68% | 31.61% | 41.25% | -9.96% | 6.61% |
| Q1 returns | N/A | -7.3% | -4.62% | 9.63% | -10.24% | -6.15% |
| Q2 returns | N/A | -9.48% | 14.79% | 4.52% | 4.99% | 13.6% |
| Q3 Returns | N/A | 8.78% | 8.11% | 19.84% | -3.86% | N/A |
| Q4 Returns | N/A | 0.04% | 11.2% | 2.86% | -0.62% | N/A |
Expense ratio: 2.39%
Inclusive of GST
Exit load
0.50% on or before 3M, NIL after 3M
| Alpha | -0.276032 |
| Beta | 0.9755 |
| Sharpe Ratio | 0.264791 |
| Sortino Ratio | 0.551762 |
| R-Squared | 0.8858 |
| Tracking Error | 1.4483 |
| Downside Risk | 18.857 |
| Std. Deviation (Annualised) | 14.9681 |
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Expense Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Growth | 9.18% | 6.67% | -0.99% | -3.59% | 7.1% | 27.02% | 16.23% | 0% | 19.44% | 6,293.14 | 1.87 | 0.39 | Very High |
| UTI Healthcare Fund - Regular Plan - IDCW | 7.91% | 7.54% | 0.1% | -2.35% | 8.33% | 24.87% | 13.99% | 12.81% | 14.66% | 1,055.53 | 2.28 | 0.35 | Very High |
| SBI Healthcare Opportunities Fund - Regular Plan - IDCW | 5.71% | 8.21% | 0.45% | -1.13% | 4.56% | 24.83% | 15.56% | 12.3% | 16.26% | 4,063.64 | 1.93 | 0.37 | Very High |
| Mirae Asset Healthcare Fund - Regular Plan - Growth | 6.15% | 10.25% | 3.03% | 0.11% | 9.4% | 23.81% | 14.41% | 0% | 19.42% | 2,753.72 | 1.94 | 0.34 | Very High |
| Aditya Birla Sun Life Pharma & Healthcare Fund - Regular Plan - Growth | 4.7% | 6.4% | 1.22% | -1.71% | 5.37% | 22.75% | 12.57% | 0% | 18.41% | 858.87 | 2.30 | 0.33 | Very High |
| Nippon India Pharma Fund - Growth | 5.58% | 6.09% | 0.67% | -3.68% | 4.04% | 22.1% | 13.33% | 14.48% | 19.73% | 7,898.24 | 1.82 | 0.32 | Very High |
| Tata India Pharma & Healthcare Fund - Regular Plan - Growth | 6.85% | 5.21% | -3.15% | -4.34% | 2.3% | 22.03% | 13.39% | 12.21% | 11.21% | 1,229.42 | 2.15 | 0.30 | Very High |
| DSP Healthcare Fund - Regular Plan - Growth | 8.21% | 4.38% | -0.83% | -4.8% | 4.87% | 21.77% | 13.64% | 0% | 20.1% | 2,891.76 | 1.94 | 0.31 | Very High |
| LIC MF Healthcare Fund - Regular Plan - Growth | 7.33% | 7.14% | -1.96% | -3.4% | 4.69% | 20.94% | 10.57% | 0% | 16.19% | 78.30 | 2.36 | 0.29 | Very High |
| ITI Pharma & Healthcare Fund - Regular Plan - Growth Current | 8.1% | 8.47% | -2.98% | -5.82% | 0.32% | 19.48% | 0% | 0% | 10.95% | 211.30 | 2.35 | 0.25 | Very High |
| Instrument Allocation | Instrument | Assets % |
|---|---|---|
|
|
Domestic Equities | 96.90% |
| Cash & Cash Equivalents and Net Assets | 3.10% |
| Sector Allocation | Sector | Assets % |
|---|---|---|
| Pharmaceuticals & Biotechnology | 68.97% | |
| Healthcare Services | 21.02% | |
| Others | 3.10% | |
| Chemicals & Petrochemicals | 2.65% | |
| Consumer Durables | 1.29% | |
| Insurance | 1.26% | |
| Industrial Manufacturing | 0.91% | |
| Healthcare Equipment & Supplies | 0.79% |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 12.40% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 8.83% |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | Domestic Equities | 6.25% |
| Max Healthcare Institute Ltd. | Healthcare Services | Domestic Equities | 5.22% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.82% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.44% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.36% |
| Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.24% |
| Fortis Healthcare Ltd. | Healthcare Services | Domestic Equities | 3.11% |
| Net Receivables / (Payables) | Cash & Cash Equivalents and Net Assets | 3.10% | |
| Cohance Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.08% |
| Neuland Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.05% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.93% |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.69% |
| Aster DM Healthcare Ltd. | Healthcare Services | Domestic Equities | 2.24% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.91% |
| Sai Life Sciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.84% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.82% |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.79% |
| Park Medi World Ltd. | Healthcare Services | Domestic Equities | 1.67% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.64% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.50% |
| Linde India Ltd. | Chemicals & Petrochemicals | Domestic Equities | 1.37% |
| Shaily Engineering Plastics Ltd. | Consumer Durables | Domestic Equities | 1.29% |
| Jubilant Ingrevia Ltd. | Chemicals & Petrochemicals | Domestic Equities | 1.28% |
| SBI Life Insurance Company Ltd. | Insurance | Domestic Equities | 1.26% |
| FDC Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.21% |
| Piramal Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.20% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.19% |
| Healthcare Global Enterprises Ltd. | Healthcare Services | Domestic Equities | 1.09% |
| Rainbow Children's Medicare Ltd. | Healthcare Services | Domestic Equities | 0.99% |
| Glaxosmithkline Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.94% |
| Standard Engineering Technology Ltd. | Industrial Manufacturing | Domestic Equities | 0.91% |
| Shilpa Medicare Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.88% |
| Poly Medicure Ltd. | Healthcare Equipment & Supplies | Domestic Equities | 0.79% |
| Caplin Point Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.78% |
| Supriya Lifescience Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.77% |
| Zydus Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.65% |
| Syngene International Ltd. | Healthcare Services | Domestic Equities | 0.45% |
| Total | 100.00% |
RETURNS
It is an Open ended scheme that primarily invests in Sector Funds.
The investment objective of the scheme is to seek to generate long term capital appreciation throughinvesting in equity and equity related securities of companies engaged in Pharma and Healthcare.However, there can be no assurance or guarantee that the investment objective of the Scheme would be achieved.
The scheme benchmark is the Nifty Healthcare Index - TRI
It is classified as Very High Risk, suitable for investors with a Very High risk appetite.
Returns Delivered by the funds are as follows:
1-year: 4.64%
3-year: 21.6%
5-year: 0%
Top holdings include names such as:
The NAV is around ₹16.73 (approx.) for the ITI Pharma & Healthcare Fund - Regular Plan - Growth.
The fund’s AUM is approximately ₹230 Cr.
The expense ratio for the Regular Plan is 2.39.
0.50% on or before 3M, NIL after 3M.
Minimum SIP starts at ₹1000.
The minimum lump sum investment is ₹5000. Often platforms may require higher in practice, but the statutory minimum remains the same.
You can start a SIP through:
Broker/agent platform like Sharescart.
Enter KYC details, choose the Regular Growth option, set SIP amount/frequency, and submit.
Yes. You can modify your SIP amount or frequency anytime online through the Sharescart platform.
You can redeem online via the Sharescart platform — choose the scheme, select the amount/units, and submit. Proceeds are credited to your bank account.
The fund managers: Animesh Singh, Nilay Dalal
This fund is suitable for investors with a Very High risk tolerance.
Get personalized Portfolio Management Services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
